The almost universal increase in the incidence of non-Hodgkin lymphoma over recent decades ( 1 -3 ) and the lack of satisfactory explanations for this phenomenon ( 4 -7 ) have led us to focus on possible risk factors whose prevalence has risen in a similar pattern. If such a risk factor is highly prevalent in the population, even a small change in its magnitude may explain at least part of the observed increase in non-Hodgkin lymphoma. Obesity may be such a risk factor because its prevalence has expanded globally ( 8 ) . Although rates of Hodgkin lymphoma have not risen simultaneously with those of non-Hodgkin lymphoma ( 9 ) , both types of lymphoma are strongly associated with immune suppression ( 10 -14 ) , and they may share other risk factors.
Several studies ( 15 -24 ) have investigated the association between obesity and the risk of lymphoma. Most studies ( 15 -17 , 19 -21 ) have been limited by low numbers of case patients, and all but two studies ( 21 , 24 ) considered non-Hodgkin lymphoma as a single disease entity rather than analyzing its histopathologic subtypes. Five of the 10 studies of the association found a statistically signifi cant positive association between obesity and lymphoma incidence ( 18 , 20 , 23 , 24 ) or mortality ( 22 ) , whereas the rest detected no association ( 15 -17 , 19 , 21 ) . Cerhan et al. ( 21 ) reported no overall association between anthropometric characteristics (including body mass index [BMI] ) and risk of overall non-Hodgkin lymphoma, diffuse lymphoma, or follicular lymphoma. However, they detected a weak positive association between BMI and B-cell chronic lymphocytic leukemia and an inverse association between BMI and small lymphocytic lymphoma. In contrast, Skibola et al. ( 24 ) found that risks of non-Hodgkin lymphoma, diffuse largecell lymphoma, and follicular lymphoma were positively associated with an overweight or obese status compared with a normal-weight status.
The results from these previous studies and the evident importance of rigorous histopathologic classifi cation to allow assessment of subtype-specifi c associations emphasized the need for further examination of the association between obesity and risk of lymphoma. We have gathered the largest known population-based sample of malignant lymphoma cases that have been uniformly classifi ed according to the current World Health Organization (WHO) classifi cation of hematopoietic and lymphoid tumors ( 25 ) . With these case patients and a comparable number of population-based control subjects, we conducted a case -control study to investigate whether BMI is associated with the development of various malignant lymphoma subtypes.
2000, to August 30, 2002 , and in Sweden from October 1, 1999 , to April 15, 2002 ( 26 ) . Danish participants in a regional pilot phase study beginning on November 1, 1999, were also included. All study participants were required to have suffi cient knowledge of the Danish or Swedish language to answer questions in a telephone interview and to have no history of organ transplantation, of a positive test for human immunodefi ciency virus (HIV), or of prior hematopoietic malignancy.
Case patients were defi ned as all patients with a fi rst, incident, and morphologically verifi ed diagnosis of non-Hodgkin lymphoma (International Classifi cation of Diseases [ICD]-10 codes C82-C85, C88.0, C91.3 -5, and C91.7), including chronic lymphocytic leukemia (ICD-10 code C91.1), or Hodgkin lymphoma (ICD-10 code C81) ( 27 ) . In both countries, individuals with prevalent cases of Hodgkin lymphoma diagnosed in 1999 were also included. We identifi ed patients with incident cases of these diseases through a rapid case ascertainment system organized for this study, consisting of a network of contact physicians from all clinical departments where malignant lymphomas are treated, for a total of 39 internal medicine, hematology, oncology, and clinical pathology departments in Denmark and 118 in Sweden. Continuous collaboration with the Danish National Pathology Registry and the six regional cancer registries in Sweden, both with an estimated coverage of approximately 100% ( 28 ) (personal communication, Inge Gram, Danish Pathology Registry), ensured complete reporting through the network.
Control subjects were randomly sampled from the entire Danish and Swedish populations by use of continuously updated, computerized population registers. We sampled a subset of control subjects every 6 months during the study period and frequency-matched them to the expected distribution of case patients with non-Hodgkin lymphoma in each country by age (in 10-year intervals) and sex.
Within the study base and time period, 3740 case patients (83%) of all those diagnosed with malignant lymphoma participated; the remaining case patients did not participate because 7% had died, 4% were physically or mentally incapacitated, 5% refused to participate, and 1% had physicians who refused to let them participate. Participation among case patients with Hodgkin lymphoma (91%) was higher than that of case patients with non-Hodgkin lymphoma (81%). The median time between diagnosis and interview was 85 days (range = 0 days to 4.2 years, including that for case patients with prevalent Hodgkin lymphoma). In the same area and time, 3187 control subjects (71%) of all potential controls consented to participate in the study. All participants provided informed consent before the interview. This study was approved by all regional ethics committees in Denmark and in Sweden and by the U.S. National Institutes of Health, the Swedish Cancer Society, and Plan Denmark, the funding sources for this study.
Exposure Assessment
All study participants completed a telephone interview including questions on current height, normal adult weight, family background, smoking habits, sun exposure, medical history, family medical history, education, occupation, childhood environment, and other possible risk factors for lymphoma. A subset of about half of the participants from Sweden also completed a self-administered written food frequency questionnaire, assessing dietary habits.
BMI was calculated as weight (in kilograms) divided by height (in meters) squared. BMI status was then categorized according to WHO standards for adults ( 29 ) as follows: less than 18.5 kg/m 2 was underweight, 18.5 -24.9 kg/m 2 was normal weight, 25.0 -29.9 kg/m 2 was overweight, 30.0 -34.9 kg/m 2 was obese, and 35.0 kg/m 2 or more was highly and morbidly obese (referred to herein as highly obese). For analyses of the less common nonHodgkin lymphoma subtypes and Hodgkin lymphoma, we combined the two upper categories into a single category (referred to as " obese " ) because of the small numbers of individuals in these groups. In analyses using the WHO cutoffs for BMI, we used individuals with a BMI of 18.5 -24.9 kg/m 2 (normal-weight status) as the reference group. In separate analyses, individuals with a BMI of 25.0 kg/m 2 or more (overweight status) and those with a BMI of less than 25.0 kg/m 2 (non-overweight status) were compared.
Because BMI was not evenly distributed in the population, with about half of case patients and control subjects falling in the normal range, BMI was also categorized into quartiles according to the following distribution among control subjects: less than 22.8 kg/m 2 was quartile 1, 22.8 -24.9 kg/m 2 was quartile 2, 25.0 -27.5 kg/m 2 was quartile 3, and 27.6 kg/m 2 or more was quartile 4. In the analyses using these categories, we used a BMI of less than 22.8 kg/m 2 (quartile 1) as the reference group. BMI was additionally considered as a continuous variable.
We considered the following potential confounders: age (in 5-year categories, except for the category including ages 18 -24 years), sex, country of residence (Denmark or Sweden), smoking status (never, former, or current smokers of cigarettes daily for at least 1 year), history of autoimmune disease (yes or no), history of skin cancer (yes or no), family history of cancer (yes or no), history of blood transfusion (yes or no), outdoor occupation (yes or no), occupation involving regular exposure to pesticides (yes or no), education level (9 years or less, 10 -12 years, or 13 years or more), sunbathing habits 5 -10 years ago (never, less than or equal to one time per week, two to three times per week, or four or more times per week), history of sunburns 5 -10 years ago and during childhood (never, less than one per year, one per year, or two or more per year), sun or beach vacations abroad (never, one to fi ve times, six to 20 times, or more than 20 times), solarium use (never, fewer than 10 times, 10 -49 times, or 50 times or more), and dietary consumption of certain foods and beverages including dairy products, fried red meat, and fruits and vegetables (quartiles of intake).
Histopathology
The histopathologic review of cases has been described in detail elsewhere ( 26 ) . Briefl y, review of tumor material from case patients in Denmark was performed within the Danish Lymphoma Group Registry (LYFO) ( 30 ) , where specimens from 10% of all incident case patients in the country are continuously chosen at random and reviewed by expert hematopathologists. In all but 20% of our study's case patients, the diagnostic tumor specimens underwent primary evaluation by a LYFO-approved senior hematopathologist. The disease subtype of all case patients was subsequently classifi ed according to the current WHO classifi cation of hematopoietic and lymphoid tumors ( 25 ) . As specifi ed by the WHO classifi cation system, we classifi ed small lymphocytic lymphoma in the same subgroup as chronic lymphocytic leukemia (collectively referred to here as chronic lymphocytic leukemia).
In Sweden, specimens from all case patients were histopathologically evaluated by a senior hematopathologist or cytologist and classifi ed according to the WHO classifi cation ( 25 ) . Only 1.5% of original tumor slides were not retrieved and evaluated; for those 35 case patients, the results of the primary morphologic and immunohistochemical investigation were evaluated. Of the 3 740 case patients in the study, 3055 were classifi ed as having non-Hodgkin lymphoma, 618 were classifi ed as having Hodgkin lymphoma, and 67 were classifi ed as having unspecifi ed lymphoma.
Statistical Analysis
Differences in the distribution of BMI between case patients and control subjects were tested with two-sided t tests. Unconditional logistic regression analysis was used to estimate the associations of risk for overall non-Hodgkin lymphoma, non-Hodgkin lymphoma subtypes, and Hodgkin lymphoma with height, weight, and BMI, which were coded as indicator variables. All multivariable models were adjusted for age (with indicator variables for 5-year intervals), sex, and country. Other potential confounders were considered on the basis of prior knowledge of their being risk factors for malignant lymphoma or because their addition to the statistical model appreciably changed the estimates of association ( 31 ) . Tests for linear trend were conducted with BMI coded as an ordinal variable with four or fi ve levels, defi ned by the median values in each category or quartile. Estimates were stratifi ed by age (younger than 60 years or 60 years or older for case patients with non-Hodgkin lymphoma; younger than 45 years or 45 years or older for case patients with Hodgkin lymphoma), sex, or smoking status. We evaluated heterogeneity of the stratifi ed associations with a likelihood ratio test for the statistical signifi cance of an interaction term between BMI and the potential modifi er. Analyses were performed with the SAS System software, release 8.2 (SAS Institute, Cary, NC, 1999 -2001). All statistical tests were two-sided. Table 1 presents the distribution of age, sex, country of residence, height, weight, and BMI among control subjects and case patients with overall non-Hodgkin lymphoma, diffuse large Bcell lymphoma, chronic lymphocytic leukemia, follicular lymphoma, T-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma (composed mostly of mucosa-associated lymphoid tissue lymphoma with a minority of nodal and splenic marginal zone lymphomas), lymphoplasmacytic lymphoma, and Hodgkin lymphoma. Case patients with Hodgkin lymphoma were also grouped into younger (younger than 45 years) and older (45 years or older) patients, in accordance with previous studies ( 32 -34 ) showing that the etiology of Hodgkin lymphoma may differ by age group. Before adjustment for confounders, the mean BMI was statistically signifi cantly higher in case patients with diffuse large B-cell lymphoma (mean BMI = 26.0 kg/m 2 ) than in control subjects (mean BMI = 25.5 kg/m 2 ; difference of the means = 0.5 kg/m 2 , 95% CI = 0.2 to 0.9 kg/m 2 ; P = .002). Conversely, the mean BMI in younger case patients with Hodgkin lymphoma (mean BMI = 24.1 kg/m 2 ) was statistically signifi cantly lower than in control subjects (difference of the means = −1.3 kg/m 2 , 95% CI = −1.8 to −0.9 kg/m 2 ; P <.001).
R ESULTS
Average BMI was also statistically non-signifi cantly higher in case patients with mantle cell lymphoma (mean BMI = 26.0 kg/ m 2 ) than in control subjects (difference in means = 0.5 kg/m 2 , 95% CI = −0.2 to 1.2 kg/m 2 ; P = .08), and lower in case patients with marginal zone lymphoma (mean BMI = 24.9 kg/m 2 ) than in control subjects (difference of the means = -0.6 kg/m 2 , 95% CI = −1.3 to 0.2 kg/m 2 ; P = .06).
After adjusting for age, sex, and country, we observed no association between BMI and risk of non-Hodgkin lymphoma overall or between BMI and risk of Hodgkin lymphoma among younger or older adults ( Table 2 ) . We observed borderline statistically signifi cant positive associations between an overweight status (BMI of 25 -29.9 kg/m 2 ), compared with a normal-weight status (BMI of 18.5 -24.9 kg/m 2 ), and risk of diffuse large Bcell lymphoma (OR = 1.2, 95% CI = 1.0 to 1.4) or of mantle cell lymphoma (OR = 1.3, 95% CI = 0.9 to 1.9). In contrast, we observed a marginally inverse association between BMI and risk of chronic lymphocytic leukemia (OR = 0.8, 95% CI = 0.7 to 1.0). However, we found no statistically signifi cant association between an obese status (BMI of 30.0 kg/m 2 or more) and risk of any form of malignant lymphoma evaluated.
We found some evidence that risk of diffuse large B-cell lymphoma was positively associated with a highly obese status (BMI of 35.0 kg/m 2 or more), compared with a normal-weight status, and we also found a statistically signifi cant positive trend between increasing BMI and risk of diffuse large B-cell lymphoma (OR = 1.5, 95% CI = 0.9 to 2.4; P trend across all categories of BMI = .05). We also observed a marginally statistically significant association between increasing BMI and decreasing risk of chronic lymphocytic leukemia ( P trend = .04), although the risk estimate comparing highly obese with normal-weight persons was not statistically signifi cant (OR = 0.6, 95% CI = 0.3 to 1.2). In contrast, there was no association between obesity and risk of non-Hodgkin lymphoma overall (for highly obese individuals compared with normal weight individuals, OR = 0.9, 95% CI = 0.6 to 1.3; P trend = 0.27). When we categorized all individuals into two groups with the cut point at a BMI of 25.0 kg/m 2 , those with a BMI of 25.0 kg/m 2 or more, compared with those with a lower BMI, had a statistically signifi cant higher risk of diffuse large B-cell lymphoma (OR = 1.2, 95% CI = 1.0 to 1.4) and a lower risk of chronic lymphocytic leukemia (OR = 0.8, 95% CI = 0.7 to 1.0).
Further adjustment for other potential confounders, including smoking status, history of rheumatoid arthritis, history of skin cancer, family history of cancer, history of blood transfusion, outdoor occupation, occupation regularly involving pesticides, education level, sunbathing habits, sunburn history, sun vacations abroad, and solarium visits, had minimal effect on all estimates (less than a 10% change). Information on dietary habits was available for only a subset of 597 case patients with non-Hodgkin lymphoma and 467 control subjects in Sweden. In this group, the results adjusted for dietary intake of dairy products, fried red meat, and fruits and vegetables (all of which were statistically signifi cantly associated with non-Hodgkin lymphoma risk; E. T. Chang, K. Ekström Smedby, S. M. Zhang, H. Hjalgrim, M. Melbye, Å. Öst, B. Glimelius, A. Wolk, H.-O. Adami, unpublished results) remained consistent with the overall fi ndings. That is, we found no association between a high BMI and risk of overall non-Hodgkin lymphoma or most non-Hodgkin lymphoma subtypes, except for statistically non-signifi cant associations between a high BMI and an increased risk of diffuse 189 (6) 89 (3) 38 (5) 4 (1) 14 (2) 18 (9) 1 (1) 3 (3) 1 (1) 177 (43) 0 (0)
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large B-cell lymphoma and a decreased risk of chronic lymphocytic leukemia (data not shown). When we categorized BMI by quartiles, we found no association between high BMI and risk of non-Hodgkin lymphoma, most non-Hodgkin lymphoma subtypes, or Hodgkin lymphoma ( Table 3 ). However, we found a statistically signifi cant increased risk of diffuse large B-cell lymphoma for people in the highest BMI quartile (27.6 kg/m 2 or more) compared with those in the lowest quartile (less than 22.8 kg/m 2 ) (OR = 1.4, 95% CI = 1.1 to 1.7; P trend across all quartiles of BMI = .01). We found no association between the BMI quartile and the risk of mantle cell lymphoma (OR = 1.1, 95% CI = 0.6 to 1.8; P trend = .56) or of chronic lymphocytic leukemia (OR = 0.9, 95% CI = 0.7 to 1.1, P trend = .21), in contrast to the associations that we detected when we compared overweight status with normal-weight status. When we treated BMI as a continuous variable, we found that BMI was statistically signifi cantly associated with only the risk of diffuse large B-cell lymphoma (for each 5 kg/m 2 increase in BMI, OR = 1.1, 95% CI = 1.0 to 1.2; P trend = .01). Additional adjustment for possible confounders had negligible effect on all estimates of association (data not shown), and results in the dietary subset were consistent with the overall results.
To examine whether the association between BMI and lymphoma risk varied by sex, we estimated risks separately for men and women and found no heterogeneity of the association by sex, whether BMI was categorized by WHO standards or by quartile (data not shown). We also found no heterogeneity in the association between older (age 60 years or older for non-Hodgkin lymphomas, or age 45 years or older for Hodgkin lymphoma) and younger persons or among never, former, and current smokers (data not shown).
Independent associations of height and weight with risk of lymphoma were evaluated separately. After adjusting for age, sex, and country, we found no association between either height or weight (categorized into quartiles) and the risk of non-Hodgkin or Hodgkin lymphoma overall or the risk of any major histopathologic subtype except for that of chronic lymphocytic leukemia (data not shown). We found that the risk of chronic lymphocytic leukemia was statistically signifi cantly associated with the highest quartile of height (taller than 179 cm), compared with the lowest quartile (165 cm or shorter)(OR = 1.7, 95% CI = 1.2 to 2.4).
D ISCUSSION
In this large-scale population-based case -control study of malignant lymphoma, we detected no association between BMI and risk of most subtypes of non-Hodgkin lymphoma or risk of Hodgkin lymphoma among younger or older adults. However, we found a weak but statistically signifi cant positive association between high BMI and risk of diffuse large B-cell lymphoma. These fi ndings were not modifi ed by age, sex, or smoking status and were apparently not confounded by known risk factors for malignant lymphoma or possible infl uences on BMI such as smoking, education, and diet.
Although we observed no statistically signifi cant associations between obesity, as defi ned by the WHO, and risk of any form of lymphoma examined, we did detect borderline statistically signifi cant associations between an overweight status and the risk of diffuse large B-cell lymphoma, mantle cell lymphoma, or chronic lymphocytic leukemia, and between a highly obese status and the risk of diffuse large B-cell lymphoma. When we categorized BMI into quartiles or treated it as a continuous variable, we found no association with the risk of non-Hodgkin lymphoma overall, but we did fi nd a statistically signifi cant positive association between high BMI and the risk of diffuse large B-cell lymphoma. The fact that the highest quartile of BMI was associated with risk of diffuse large B-cell lymphoma, but that obesity was not, most likely resulted from the low prevalence of obesity in the study population (only 11% among control subjects), which reduced the power to detect an association between an obese status and lymphoma risk. However, the fact that our fi ndings varied slightly depending on the procedure used to categorize BMI emphasizes the fact that the marginal association with risk of diffuse large B-cell lymphoma was potentially spurious. Previous fi ndings of a positive association between an obese status and the risk of overall non-Hodgkin lymphoma in a handful of studies ( 18 , 20 , 22 -24 ) may have been infl uenced by a possible positive association with risk of diffuse large B-cell lymphoma. This subtype generally accounts for more than 30% of all non-Hodgkin lymphoma, making it the most common subtype of non-Hodgkin lymphoma in various populations ( 35 -42 ) . Overall survival of patients with diffuse large B-cell lymphoma (less than 50% after 5 years) is similar to or lower than that for other common subtypes of non-Hodgkin lymphoma, including follicular lymphoma and chronic lymphocytic leukemia ( 35 , 43 ) . Therefore, it is possible that the fi ndings of Calle et al. ( 22 ) -that obesity was associated with increased risk of non-Hodgkin lymphoma mortality -also refl ected a high proportion of diffuse large B-cell lymphoma in the case population. Alternatively, it is possible that obesity contributes to lymphoma mortality but not to its incidence. If true, this association could have resulted in some selection bias among the case patients in our study if those who survived were leaner than those who died. Another difference between our study and previous investigations is that others have generally excluded chronic lymphocytic leukemia -largely because no other study has classifi ed non-Hodgkin lymphoma according to the current WHO system, which includes chronic * Estimates adjusted for age (5-year intervals), sex, and country. OR = odds ratio; CI = confi dence interval; ref. = referent. † BMI status was missing for 29 control subjects, 10 non-Hodgkin lymphoma case patients (including one diffuse large B-cell lymphoma case patient, two chronic lymphocytic leukemia case patients, four follicular lymphoma case patients, one T-cell lymphoma case patient, and one marginal zone lymphoma case patient), and four Hodgkin lymphoma case patients. The total number of subjects analyzed does not include those with missing data.
‡ For non-Hodgkin lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and follicular lymphoma. § For T-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, and Hodgkin lymphoma.
║ P values were determined by the two-sided Wald chi-squared test. * Estimates adjusted for age (5-year intervals), sex, and country. OR = odds ratio; CI = confi dence interval. ref. = referent. † BMI status was missing for 29 control subjects, 10 non-Hodgkin lymphoma case patients (including one diffuse large B-cell lymphoma case patient, two chronic lymphocytic leukemia case patients, four follicular lymphoma case patients, one T-cell lymphoma case patient, and one marginal zone lymphoma case patient), and four younger Hodgkin lymphoma case patients. The total number of subjects analyzed does not include those with missing data.
‡ P values were determined by the two-sided Wald chi-squared test.
lymphocytic leukemia as a non-Hodgkin lymphoma subtypefor which we did not detect a positive association with BMI. Although our fi nding of a positive association between high BMI status and the risk of diffuse large B-cell lymphoma agrees with that of Skibola et al. ( 24 ) , they also detected a positive association between obesity and the risk of overall non-Hodgkin lymphoma or of follicular lymphoma, which we did not observe. Our results are also consistent with several other studies detecting no association between BMI and non-Hodgkin lymphoma ( 15 -17 , 19 , 21 ) . Although our results agree for the most part with those of Cerhan et al. ( 21 ) , who reported no association between BMI and risk of non-Hodgkin lymphoma, of follicular lymphoma, or of diffuse lymphoma, we did not detect a marginal positive association with risk of chronic lymphocytic leukemia. If anything, the association between BMI and the risk of chronic lymphocytic leukemia that we detected was slightly inverse, driven mostly by an apparent positive association between height and the risk of chronic lymphocytic leukemia, which was not observed by Cerhan et al. However, that group distinguished chronic lymphocytic leukemia from small lymphocytic lymphoma, which we combined with chronic lymphocytic leukemia as specifi ed by the WHO classifi cation ( 25 ) . If Cerhan et al. ( 21 ) had combined chronic lymphocytic leukemia with small lymphocytic lymphoma, for which they observed a statistically nonsignifi cant inverse association with BMI, they may also have obtained null results. In any case, the association of chronic lymphocytic leukemia with obesity in our study and in that of Cerhan et al. was weak at best. Our observation of a positive association between height and the risk of chronic lymphocytic leukemia needs to be confi rmed in other study populations.
No biologic mechanisms have been proposed that could explain a potential association between high BMI and the risk of non-Hodgkin lymphoma or Hodgkin lymphoma. It is also unclear why high BMI should be associated with a higher risk of diffuse large B-cell lymphoma but not of overall non-Hodgkin lymphoma, other subtypes of non-Hodgkin lymphoma, or Hodgkin lymphoma; a possible explanation lies in the fact that the various forms of lymphoma are distinct disease entities ( 25 ) with presumably different etiologies. The positive association between obesity and endocrine-related malignancies might be explained by increased levels of endogenous hormones, including sex steroids, insulin, or insulin-like growth factor I ( 44 , 45 ) , but a causative role of these hormones in lymphomagenesis has not been established ( 46 -48 ) . From observations on laboratory animals fed calorie-restricted diets ( 49 ) , body mass also appears to affect cell proliferation ( 50 ) and apoptosis ( 51 ) . Moreover, obesity may impair immune function ( 52 , 53 ) , which is critical to the development of non-Hodgkin lymphoma and Hodgkin lymphoma ( 10 -14 ) .
Our fi ndings should be interpreted in light of several limitations. BMI is a widely accepted and used index of weight adjusted for height, especially in population-based studies ( 29 , 54 , 55 ) . However, the validity of BMI as a measure of an overweight or obese status varies among ethnic groups, which differ in weight distribution and body composition. Therefore, results from a Scandinavian population may not necessarily be applicable to other populations. We lacked a direct measure of general or central adiposity or lean body mass, any or all of which may be more relevant to lymphoma risk. Furthermore, we did not have data on weight change or weight cycling over time and, therefore, were unable to evaluate the association between time trends in weight and lymphoma risk.
Because the disease may have affected the current weight of case patients, we asked participants to report their normal or usual adult weight. It is possible, although unlikely, that there were systematic differences between case patients and control subjects in their recollection of normal weight. However, it is not clear whether having been diagnosed with lymphoma would cause case patients to remember their previous weight more or less accurately or as being higher or lower than it was. We compared the country-specifi c distributions of BMI among the control subjects with published data from the Danish ( 56 ) and Swedish ( 57 ) populations and found that the reported distributions were very similar to those in our study, suggesting a lack of systematic misclassifi cation among the control subjects. However, grouping BMI into categories and quartiles may also have introduced a degree of misclassifi cation, with unpredictable effects.
Other biases could also explain the results. Although enrollment rates were high among both case patients and control subjects, reasons for nonparticipation differed between the two groups, especially because the most common reason for nonparticipation among the case patients was death. Selection bias could have produced overestimates of the association between BMI and lymphoma risk if eligible, overweight control subjects were less likely to enroll in the study and/or if eligible, overweight lymphoma patients were more likely to survive or participate. Alternatively, selection bias could have resulted in underestimates if overweight control subjects were more likely to enroll and/or overweight patients were more likely to die or refuse to participate. The low prevalence of individuals with an obese or underweight status in our study population reduced our ability to assess the associations between very high or very low BMI with risk of lymphoma, especially with the less common subtypes of non-Hodgkin lymphoma, including T-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma. One explanation for the lack of association between high BMI and the risk of some lymphoma subtypes could, therefore, be lack of statistical power, especially given that the magnitude of any association appears to be low. However, it is unlikely that our observation of no association between high BMI and overall non-Hodgkin lymphoma risk was caused by lack of power, given the large number of case patients in our study. As in any observational study, confounding by unknown factors or residual confounding caused by imperfect exposure assessment cannot be ruled out.
Finally, the possible association between increased BMI and risk of diffuse large B-cell lymphoma could be accounted for by chance. This explanation has to be considered because many tests of association were performed on several non-Hodgkin lymphoma subtypes, so that a few statistically signifi cant fi ndings would be expected to arise by chance alone. However, if a BMI of 27.6 kg/m 2 or more is in fact associated with a 40% increased risk of diffuse large B-cell lymphoma, as observed in our study, then a high BMI might account for a nontrivial proportion of diffuse large B-cell lymphoma, given the high prevalence of this level of BMI, especially in Western populations. Diffuse large B-cell lymphoma is generally the most common subtype of nonHodgkin lymphoma worldwide ( 34 ) .
In summary, our fi ndings suggest that high BMI, including an overweight and obese status, does not play an important role in the development of overall non-Hodgkin lymphoma, most non-Hodgkin lymphoma subtypes, or Hodgkin lymphoma. We found an indication that high BMI may play a role in the development of diffuse large B-cell lymphoma. Given that our study was conducted in a fairly homogeneous population with a relatively low prevalence of obesity, our results may not be able to be generalized to other populations. However, because high BMI appears to be only a weak risk factor, if a factor at all, for a single subtype of non-Hodgkin lymphoma, the increasing incidence of overall non-Hodgkin lymphoma across recent decades is unlikely to be explained in large part by the global escalation of the prevalence of overweight and obese individuals.
